InterCure (INCR) Competitors $1.58 -0.03 (-1.58%) Closing price 09/4/2025 03:57 PM EasternExtended Trading$1.61 +0.03 (+1.58%) As of 09/4/2025 04:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock INCR vs. SCPH, CAPR, FDMT, NGNE, MREO, GALT, LFCR, TVRD, NMRA, and DMACShould you be buying InterCure stock or one of its competitors? The main competitors of InterCure include scPharmaceuticals (SCPH), Capricor Therapeutics (CAPR), 4D Molecular Therapeutics (FDMT), Neurogene (NGNE), Mereo BioPharma Group (MREO), Galectin Therapeutics (GALT), Lifecore Biomedical (LFCR), Tvardi Therapeutics (TVRD), Neumora Therapeutics (NMRA), and DiaMedica Therapeutics (DMAC). These companies are all part of the "pharmaceutical products" industry. InterCure vs. Its Competitors scPharmaceuticals Capricor Therapeutics 4D Molecular Therapeutics Neurogene Mereo BioPharma Group Galectin Therapeutics Lifecore Biomedical Tvardi Therapeutics Neumora Therapeutics DiaMedica Therapeutics scPharmaceuticals (NASDAQ:SCPH) and InterCure (NASDAQ:INCR) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, dividends, risk, institutional ownership, valuation, analyst recommendations, earnings and media sentiment. Which has more volatility & risk, SCPH or INCR? scPharmaceuticals has a beta of 0.35, meaning that its stock price is 65% less volatile than the S&P 500. Comparatively, InterCure has a beta of 1.19, meaning that its stock price is 19% more volatile than the S&P 500. Does the media favor SCPH or INCR? In the previous week, scPharmaceuticals had 6 more articles in the media than InterCure. MarketBeat recorded 6 mentions for scPharmaceuticals and 0 mentions for InterCure. scPharmaceuticals' average media sentiment score of 0.82 beat InterCure's score of 0.00 indicating that scPharmaceuticals is being referred to more favorably in the media. Company Overall Sentiment scPharmaceuticals Positive InterCure Neutral Do insiders and institutionals have more ownership in SCPH or INCR? 89.5% of scPharmaceuticals shares are held by institutional investors. Comparatively, 8.3% of InterCure shares are held by institutional investors. 4.8% of scPharmaceuticals shares are held by insiders. Comparatively, 0.2% of InterCure shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Do analysts rate SCPH or INCR? scPharmaceuticals presently has a consensus price target of $7.78, suggesting a potential upside of 39.49%. Given scPharmaceuticals' stronger consensus rating and higher possible upside, research analysts clearly believe scPharmaceuticals is more favorable than InterCure.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score scPharmaceuticals 0 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00InterCure 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has better valuation & earnings, SCPH or INCR? InterCure has higher revenue and earnings than scPharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioscPharmaceuticals$36.33M8.19-$85.15M-$1.81-3.08InterCure$64.55MN/A-$18.32MN/AN/A Is SCPH or INCR more profitable? InterCure has a net margin of 0.00% compared to scPharmaceuticals' net margin of -183.55%. InterCure's return on equity of 0.00% beat scPharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets scPharmaceuticals-183.55% -1,647.86% -71.76% InterCure N/A N/A N/A SummaryscPharmaceuticals and InterCure tied by winning 6 of the 12 factors compared between the two stocks. Get InterCure News Delivered to You Automatically Sign up to receive the latest news and ratings for INCR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding INCR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INCR vs. The Competition Export to ExcelMetricInterCureMED PRODUCTS IndustryMedical SectorNASDAQ ExchangeMarket CapN/A$10.94B$5.76B$9.85BDividend YieldN/A1.85%6.67%4.51%P/E RatioN/A21.6875.6526.43Price / SalesN/A31.25549.99119.09Price / CashN/A24.5637.0558.92Price / Book0.673.5711.176.06Net Income-$18.32M$212.34M$3.29B$266.28M7 Day Performance-0.94%-2.90%0.18%-0.33%1 Month Performance8.93%7.70%6.28%3.43%1 Year Performance-22.68%-8.61%55.11%23.10% InterCure Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INCRInterCure0.2284 of 5 stars$1.59-1.6%N/A-21.1%$0.00$64.55M0.00350Gap DownSCPHscPharmaceuticals4.1202 of 5 stars$5.51+0.1%$12.00+118.0%+9.6%$293.42M$36.33M-3.0430Short Interest ↑High Trading VolumeCAPRCapricor Therapeutics2.8967 of 5 stars$6.36+1.2%$22.56+254.9%+36.6%$291.24M$22.27M-3.88101FDMT4D Molecular Therapeutics2.6261 of 5 stars$6.15-0.2%$30.40+394.7%-57.7%$286.13M$40K-1.74120News CoverageGap UpNGNENeurogene2.4238 of 5 stars$19.76+6.9%$46.17+133.6%-43.2%$281.37MN/A-4.5790Positive NewsMREOMereo BioPharma Group2.6608 of 5 stars$1.77+3.2%$7.40+319.3%-60.2%$280.64M$10M-25.2140GALTGalectin Therapeutics1.923 of 5 stars$4.41+2.9%$6.00+36.2%+90.6%$280.33MN/A-6.849LFCRLifecore Biomedical0.6961 of 5 stars$7.49-1.6%$8.00+6.9%+88.2%$279.98M$128.87M-5.71690News CoverageAnalyst ForecastTVRDTvardi TherapeuticsN/A$29.67-0.8%$64.25+116.5%N/A$278.31M$7.14M0.0080Gap DownNMRANeumora Therapeutics3.2191 of 5 stars$1.72-0.9%$7.14+316.5%-85.2%$277.74MN/A-1.09108Short Interest ↓DMACDiaMedica Therapeutics1.8855 of 5 stars$5.35-6.4%$12.33+130.7%+35.6%$277.32MN/A-7.7820Trending NewsAnalyst DowngradeInsider Trade Related Companies and Tools Related Companies SCPH Competitors CAPR Competitors FDMT Competitors NGNE Competitors MREO Competitors GALT Competitors LFCR Competitors TVRD Competitors NMRA Competitors DMAC Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:INCR) was last updated on 9/5/2025 by MarketBeat.com Staff From Our Partners“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredOne tiny company just cracked Google’s $19B problemFor decades, this “AI metal” was trapped in labs, too slow and expensive to ever reach mass production. The...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding InterCure Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share InterCure With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free INCR Stock Alerts